A Phase II Study of AMG 337 in Patients with Stomach and Esophageal Cancers with High Levels of the MET Protein

Full Title
A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG 337 in Subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors

MET is a protein that is produced in high amounts (“amplified”) in some cancer cells. AMG 337 is an investigational drug designed to inhibit cancer growth by blocking MET activity.

In this study, researchers are evaluating the safety and effectiveness of AMG 337 in patients with inoperable or metastatic cancers of the esophagus, stomach, or junction between the esophagus and stomach (gastroesophageal junction) that show MET amplification. AMG 337 is taken once daily by mouth.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have cancer of the esophagus, stomach, or gastroesophageal junction that has spread or cannot be surgically removed.
  • Patients’ cancers must show amplification of the MET protein.
  • At least 2 weeks must pass between completion of previous treatment and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Geoffrey Ku at 646-888-4588.

Upper Gastrointestinal: Esophageal Cancer
Upper Gastrointestinal: Gastric Cancer
Related Diseases